MedTrace Logo

Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome

NCT03345953 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2020-07-30

No results posted yet for this study

Summary

This is a Group Sequential Test multicenter, randomized, double blind, placebo controlled phase II proof of concept trial with parallel groups to evaluate the efficacy and the safety of BP1.4979 15mg BID compared to placebo in RLS patients during 2 weeks double blind treatment.

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

BP 1.4979

Double blind versus placebo

DRUG

Placebo

Double blind versus placebo

Sponsors & Collaborators

Principal Investigators

  • Imad Ghorayeb, MD · Hôpital Pellegrin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-06
Primary Completion
2020-04-29
Completion
2020-04-29

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03345953 on ClinicalTrials.gov